Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4394-4399

  Yang, Lin ^a   Dan, Han C ^a   Sun, Mei ^a   Liu, Qiyuan ^a   Sun, Xia Meng ^a   Feldman, Richard I ^b   Hamilton, Andrew D ^c   Polokoff, Mark ^b   Nicosia, Santo V ^a   Herlyn, Meenhard ^d   Sebti, Said M ^a   Cheng, Jin Q ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b BAYER AG   (Germany)

^c YALE UNIVERSITY   (United States)

^d WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B SIGNALING INHIBITOR 2; PROTEIN KINASE C; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; STRESS ACTIVATED PROTEIN KINASE; TRICIRIBINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; MUTATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; FEMALE; HUMANS; IMMEDIATE-EARLY PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NIH 3T3 CELLS; NUCLEAR PROTEINS; NUCLEOSIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDAZINES; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3042743988     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0343     Document Type: Article

References (20)

1. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
2. Cheng JQ, Nicosia SV. AKT signal transduction pathway in oncogenesis. In: Schwab D, editor. Encyclopedic reference of cancer. Berlin, Germany: Springer; 2001. p. 35-7.
3. Sun M, Wang G, Paciga JE, et al. AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-7.
4. Cheng JQ, Altomare DA, Klein MA, et al. Transforming activity and cell cycle-dependent expression of the AKT2 oncogene: evidence for a link between cell cycle regulation and oncogenesis. Oncogene 1997;14:2793-801.
5. West KA, Castillo SS, Dennis PA. Activation of the P13K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-48.
6. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and β-catenin pathways. Cancer Res 2001;61: 7318-24.
7. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000;20:139-48.
8. Sun J, Blaskovic MA, Knowles D, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 1999;59:4919-26.
9. Jetzt A, Howe JA, Horn MT, et al. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res 2003;63:697-706.
10. Schweinsberg PD, Smith RG, Loo TL. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem Pharmacol 1981;30:2521-6.
11. Dan HC, Sun M, Yang L, et al. PI3K/AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002;277:35364-35370.
12. Schurmann A, Mooney AF, Sanders LC, et al. p21-activated kinase I phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol 2000;20: 453-61.
13. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
14. Xu W, Yuan X, Jung YJ, et al. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD 1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 2003;63:7777-84.
15. Wotring LL, Townsend LB, Jones LM, Borysko KZ, Gildersleeve DL, Parker WB. Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res 1990; 50:4891-9.
16. Ptak RG, Borysko KZ, Porcari AR, et al. Phosphorylation of triciribine is necessary for activity against HIV type 1. AIDS Res Hum Retroviruses 1998;14:1315-22.
17. Feun LG, Savaraj N, Bodey GP, et al. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 1984;44:3608-12.
18. Feun LG, Blessing JA, Barrett RJ, Hanjani P. A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1993;16:506-8.
19. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase AKT2 (PKBβ). Science 2001;292:1728-31.
20. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-8.